Oruka Therapeutics (NASDAQ:ORKA) Shares Up 4.3% – Should You Buy?

Oruka Therapeutics, Inc. (NASDAQ:ORKA) rose 4.3% on Wednesday . The stock traded as high as $30.32 and last traded at $30.3720. Approximately 67,821 shares traded hands during trading, a decline of 79% from the average daily volume of 330,420 shares. The stock had previously closed at $29.12.

Analyst Ratings Changes

Several research analysts have commented on the company. Wall Street Zen downgraded Oruka Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, November 16th. Piper Sandler assumed coverage on shares of Oruka Therapeutics in a research note on Thursday, December 18th. They issued an “overweight” rating and a $75.00 price objective on the stock. BTIG Research upped their target price on shares of Oruka Therapeutics from $56.00 to $63.00 and gave the company a “buy” rating in a research note on Thursday, November 13th. Guggenheim started coverage on shares of Oruka Therapeutics in a report on Monday, October 27th. They issued a “buy” rating and a $60.00 price target for the company. Finally, HC Wainwright decreased their price target on shares of Oruka Therapeutics from $45.00 to $40.00 and set a “buy” rating on the stock in a research report on Monday, October 27th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $48.88.

Oruka Therapeutics Stock Performance

The firm’s 50-day moving average price is $29.05 and its two-hundred day moving average price is $20.55. The firm has a market capitalization of $1.48 billion, a price-to-earnings ratio of -16.08 and a beta of -0.41.

Oruka Therapeutics (NASDAQ:ORKA) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.55) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.01. As a group, equities research analysts anticipate that Oruka Therapeutics, Inc. will post -3.41 EPS for the current year.

Insider Activity at Oruka Therapeutics

In related news, insider Joana Goncalves sold 7,000 shares of the firm’s stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $30.61, for a total transaction of $214,270.00. Following the completion of the transaction, the insider owned 1,518 shares in the company, valued at $46,465.98. This trade represents a 82.18% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 24.69% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. PNC Financial Services Group Inc. acquired a new stake in shares of Oruka Therapeutics in the 3rd quarter valued at $39,000. Russell Investments Group Ltd. acquired a new position in shares of Oruka Therapeutics in the 3rd quarter worth approximately $43,000. Legal & General Group Plc bought a new position in Oruka Therapeutics in the 2nd quarter valued at $28,000. Ameritas Investment Partners Inc. acquired a new position in Oruka Therapeutics in the second quarter worth $31,000. Finally, BNP Paribas Financial Markets boosted its stake in Oruka Therapeutics by 464.0% in the second quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company’s stock worth $31,000 after purchasing an additional 2,306 shares in the last quarter. 56.44% of the stock is currently owned by institutional investors and hedge funds.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.